This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Arqule Shutters Lung Cancer Study Early Due to Futility

WOBURN, Mass. ( TheStreet) -- Arqule (ARQL - Get Report) shut down a late-stage lung cancer study of tivantinib after independent monitors concluded the drug would not prolong patient survival.

Arqule shares plunged $3.09, or 62%, to $1.90 in Tuesday's pre-market session.

At its current burn rate, Arqule has approximately $1.75 per share in cash.

The phase III "MARQUEE" study enrolled 1,000 patients with newly diagnosed non-small cell lung cancer and randomized them to receive either tivantinib plus Tarceva or Tarceva alone. Tarceva is a currently approved treatment for lung cancer marketed by Roche (RHHBY) and Astellas.

After a planned interim analysis, independent monitors concluded that tivantinib would fail to improve overall survival compared to Tarceva -- the primary endpoint of the study.

On that basis, Arqule and its partner Daiichi Sankyo decided to discontinue the study.

"We are disappointed that the MARQUEE trial did not provide statistically significant results for overall survival in a disease and treatment setting which remains a major unmet medical need," said Paolo Pucci, Arqule CEO, in a statement.

Arqule said nothing Tuesday about the status of a separate phase III study of tivantinib being conducted in Asia. That study, known as "ATTENTION" stopped enrolling patients in August due to reports of suspected cases if interstitial lung disease that appeared to be more prevalent in patients treated with tivantinib.

-- Reported by Adam Feuerstein in Boston.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
RHHBY $31.57 0.00%
ARQL $1.63 0.00%
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs